GSK plc (NYSE:GSK) released headline results from a planned analysis of Part 1 of the RUBY phase 3 trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results